Nobelitin and Sorafenib Combination Therapy

ABSTRACT: To enhance hepatocellular carcinoma (HCC) treatment, the combination of Nobelitin (NOB) and Sorafenib (SOR) is being explored. Nobelitin is utilized to induce the expression of BMAL1, a circadian rhythm-related protein, with the goal of improving the effectiveness of SOR in treating HCC. This innovative strategy holds promise for optimizing treatment outcomes for HCC patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE245588 | GEO | 2024/11/16

REPOSITORIES: GEO